Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -116,0x - -128,2x | -122,1x |
| Selected Fwd EBIT Multiple | 7,6x - 8,4x | 8,0x |
| Fair Value | $9,23 - $10,26 | $9,75 |
| Upside | -41,6% - -35,1% | -38,4% |
| Benchmarks | Ticker | Full Ticker |
| 4Front Ventures Corp. | FFNT.F | PINC:FFNT.F |
| Harmony Biosciences Holdings, Inc. | HRMY | NasdaqGM:HRMY |
| Evolus, Inc. | EOLS | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | TARS | NasdaqGS:TARS |
| Corcept Therapeutics Incorporated | CORT | NasdaqCM:CORT |
| Eton Pharmaceuticals, Inc. | ETON | NasdaqGM:ETON |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| FFNT.F | HRMY | EOLS | TARS | CORT | ETON | ||
| PINC:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | NasdaqCM:CORT | NasdaqGM:ETON | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 4.2% | NM- | |
| 3Y CAGR | NM- | 29.7% | NM- | NM- | 3.2% | NM- | |
| Latest Twelve Months | 14.2% | -0.6% | 24.6% | 15.8% | 27.7% | -83.1% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -33.7% | 0.1% | -63.9% | -284.8% | 29.6% | -4133.0% | |
| Prior Fiscal Year | -7.0% | 33.0% | -17.9% | -820.5% | 22.2% | -3.8% | |
| Latest Fiscal Year | -21.2% | 26.7% | -10.2% | -65.9% | 20.3% | -5.6% | |
| Latest Twelve Months | -29.3% | 26.7% | -10.2% | -65.9% | 20.3% | -5.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.99x | 1.83x | 2.94x | 10.17x | 10.32x | 11.26x | |
| EV / LTM EBITDA | -13.3x | 6.1x | -35.7x | -15.6x | 50.6x | -397.2x | |
| EV / LTM EBIT | -10.2x | 6.8x | -28.8x | -15.4x | 50.9x | -201.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -28.8x | -10.2x | 50.9x | ||||
| Historical EV / LTM EBIT | -201.3x | -8.8x | 51.6x | ||||
| Selected EV / LTM EBIT | -116.0x | -122.1x | -128.2x | ||||
| (x) LTM EBIT | (2) | (2) | (2) | ||||
| (=) Implied Enterprise Value | 253 | 266 | 280 | ||||
| (-) Non-shareholder Claims * | (15) | (15) | (15) | ||||
| (=) Equity Value | 238 | 251 | 265 | ||||
| (/) Shares Outstanding | 26.8 | 26.8 | 26.8 | ||||
| Implied Value Range | 8.88 | 9.37 | 9.87 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 8.88 | 9.37 | 9.87 | 15.82 | |||
| Upside / (Downside) | -43.9% | -40.8% | -37.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | TARS | CORT | ETON | |
| Enterprise Value | 231 | 1,305 | 784 | 1,858 | 6,969 | 439 | |
| (+) Cash & Short Term Investments | 1 | 467 | 87 | 291 | 383 | 15 | |
| (+) Investments & Other | 0 | 109 | 0 | 3 | 220 | 0 | |
| (-) Debt | (230) | (181) | (130) | (72) | (7) | (30) | |
| (-) Other Liabilities | (0) | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 2 | 1,699 | 741 | 2,080 | 7,566 | 424 | |
| (/) Shares Outstanding | 916.4 | 57.4 | 63.6 | 41.6 | 105.5 | 26.8 | |
| Implied Stock Price | 0.00 | 29.61 | 11.65 | 50.00 | 71.71 | 15.82 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.00 | 29.61 | 11.65 | 50.00 | 71.71 | 15.82 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |